Arbutus Biopharma Corp
NASDAQ:ABUS 3:59:57 PM EDT
Earnings Announcements
Arbutus Biopharma Reports Q2 Loss Per Share Of $0.10
Published: 08/04/2022 12:06 GMT
Arbutus Biopharma Corp (ABUS) - Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update.
Q2 Loss per Share $0.10.
Q2 Revenue $14.2 Million.
Financially Strong With a Projected Cash Runway Into Q2 of 2024.
Key Milestones Across Our Chronic Hepatitis B Virus (chbv) and Pan-coronavirus Programs Remain on Track.
Revenues Were $14.2 Million for Three Months Ended June 30, 2022 Compared to $2.3 Million for Same Period in 2021.
Qtrly Loss per Share $0.10.
Q2 Earnings per Share View $-0.13, Revenue View $6.8 Million -- Refinitiv Ibes Data (analyst estimates).
Q2 Loss per Share $0.10.
Q2 Revenue $14.2 Million.
Financially Strong With a Projected Cash Runway Into Q2 of 2024.
Key Milestones Across Our Chronic Hepatitis B Virus (chbv) and Pan-coronavirus Programs Remain on Track.
Revenues Were $14.2 Million for Three Months Ended June 30, 2022 Compared to $2.3 Million for Same Period in 2021.
Qtrly Loss per Share $0.10.
Q2 Earnings per Share View $-0.13, Revenue View $6.8 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $9.37 Million
Adjusted EPS is expected to be -$0.13
Next Quarter Revenue Guidance is expected to be $8.7 Million
Next Quarter EPS Guidance is expected to be -$0.14
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.13
Next Quarter Revenue Guidance is expected to be $8.7 Million
Next Quarter EPS Guidance is expected to be -$0.14
More details on our Analysts Page.